Serum levels of 8-methoxypsoralen 2 hours after oral administration

Area of Science:

• Dermatology
• Pharmacokinetics
• Photobiology

Background:

• Psoriasis is a chronic skin condition often treated with photochemotherapy.
• 8-methoxypsoralen (8-MOP) is a photosensitizing agent used in PUVA therapy.
• Individual patient responses to 8-MOP can vary, impacting treatment efficacy and safety.

Purpose of the Study:

• To investigate the pharmacokinetic variability of 8-methoxypsoralen (8-MOP) in psoriatic patients.
• To determine the relationship between oral 8-MOP dosage, serum concentrations, and phototoxic response.
• To understand factors influencing the minimal phototoxic dose (MPD) in psoriatic patients undergoing PUVA therapy.

Main Methods:

• Oral administration of 8-methoxypsoralen (8-MOP) to psoriatic patients.
• Measurement of serum 8-MOP levels at a specific time point (2 hours post-administration).
• Determination of the minimal phototoxic UVA dose (MPD) for each patient.

Main Results:

• Significant inter-individual variability in serum 8-MOP levels was observed 2 hours after oral intake.
• No consistent correlation was found between the ingested 8-MOP dose per kilogram of body weight and the resulting serum 8-MOP concentration.
• The study did not identify a clear correlation between serum 8-MOP levels and the minimal phototoxic UVA dose required.

Conclusions:

• Oral 8-MOP pharmacokinetics exhibit considerable variability in psoriatic patients.
• Predicting phototoxic response based solely on 8-MOP dosage and serum levels is unreliable.
• Further research is needed to identify factors influencing 8-MOP efficacy and safety in PUVA therapy for psoriasis.